Q4 2024 Earnings Call Transcript March 7, 2025 Oncolytics Biotech Inc. beats earnings expectations. Reported EPS is $-0.06949, expectations were $-0.08. Operator: Good morning, and welcome to ...

Emily Powell-Heaton was eating dinner with a friend when she got a message from Ben Stiller. She tells TODAY.com that her ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...

In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with ...

A researcher at the Wintrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences received a ...

Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable ...

As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung cancer research. This optimism comes in the wake of the Food and Drug Administration’s ...

A study conducted by researchers at the University of Tartu showed a nearly five-fold enrichment of hereditary cancer ...

Cancer cells have an insatiable appetite for energy as they multiply more rapidly than normal cells. Greedy cancer cells ...

Study findings demonstrate how identifying and focusing care on a key core symptom can have the greatest impact on improving outcomes for patients receiving chemotherapy for breast cancer.

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...